Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hematopoietic and Stem Cell Transplant Clear all
Recruiting Not applicable Interventional

The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients

NCT07718204
View directory record Official record
Conditions
Hematopoietic Cell Transplant
Interventions
MedMemos
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
0 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 21, 2026, 2:43 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

NCT02724904
View directory record Official record
Conditions
Lymphoma
Interventions
Allogeneic stem cell transplantation, Fludarabine, Thiotepa, Methotrexate
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 21, 2026, 2:43 PM EDT
Terminated Phase 1 Interventional

Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation

NCT01182233
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Total Skeletal Irradiation
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

NCT03734601
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Lymphocytic Leukemia, B-cell Lymphoma, T-cell Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myelomonocytic Leukemia
Interventions
Total body irradiation (TBI), Anti-thymocyte globulin (ATG), Tacrolimus, Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI)
Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 21, 2026, 2:43 PM EDT
Recruiting Not applicable Interventional

A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

NCT07616921
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Aerobic Exercise, Resistance Training, Biospecimen Collection, Electronic Health Record Review, Survey Administration, Interview
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease

NCT03158896
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
MSCTC-0010 Dose Escalation
Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia

NCT01991457
View directory record Official record
Conditions
Adult Lymphoblastic Lymphoma
Interventions
Fludarabine, Total Body Irradiation
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

NCT02780609
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Melphalan, Dexamethasone, Autologous Hematopoietic Cell Transplantation (HCT), Fosaprepitant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

NCT02918292
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide, Total Body Irradiation (TBI), Haplo HSCT, Tacrolimus, Mycophenolate mofetil (MMF), G-CSF
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Recruiting Phase 2 Interventional

Ivosidenib as Post-HSCT Maintenance for AML

NCT06707493
View directory record Official record
Conditions
IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ivosidenib, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Atlanta, Georgia • Kansas City, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Terminated Phase 1 Interventional

Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

NCT05223699
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplasia
Interventions
MGTA-117
Biological
Lead sponsor
Magenta Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

NCT00027547
View directory record Official record
Conditions
Leukemia
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, cytarabine, fludarabine phosphate, methotrexate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 21, 2026, 2:43 PM EDT
Recruiting Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

NCT01861106
View directory record Official record
Conditions
GATA2, Immunodeficiency, MDS
Interventions
Allogeneic HSCT, Busulfan Test dose, Fludarabine (Fludara, Berlex Laboratories), Busulfan (Busulfex), Cyclophosphamide (CTX, Cytoxan), Total Body Irradiation (TBI), Mycophenolate mofetil (MMF), Tacrolimus, Equine Anti-Thymocyte Globulin
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

NCT01246206
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Tacrolimus and Thymoglobulin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 21, 2026, 2:43 PM EDT
Active, not recruiting Phase 1 Interventional

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

NCT05015426
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gamma Delta T-Cell Infusion
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

NCT01393717
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
brentuximab vedotin
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
11 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

NCT00007995
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, recombinant interferon alfa, sargramostim, busulfan, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 21, 2026, 2:43 PM EDT
Terminated Phase 3 Interventional Results available

Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

NCT00926575
View directory record Official record
Conditions
Acute Gastrointestinal Graft vs Host Disease
Interventions
oral beclomethasone 17,21-dipropionate, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Buffalo, New York • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Not applicable Interventional

Telehealth Exercise Platform to Reduce Frailty After Bone Marrow Transplant

NCT04968119
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 21, 2026, 2:43 PM EDT
Recruiting Phase 2 Interventional

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

NCT04356469
View directory record Official record
Conditions
Hemoglobinopathy (Disorder), Severe Aplastic Anemia, Bone Marrow Failure Syndrome
Interventions
Haploidentical Hematopoietic Cell Transplantation
Biological
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
0 Years to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

NCT02756572
View directory record Official record
Conditions
Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cladribine, Cyclosporine, Cytarabine, Filgrastim, Fludarabine Phosphate, Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan, Mitoxantrone Hydrochloride, Mycophenolate Mofetil, Questionnaire Administration, Sirolimus, Total-Body Irradiation, Melphalan Hydrochloride
Drug · Biological · Procedure + 2 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

NCT00060372
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Disseminated Neuroblastoma, Malignant Neoplasm, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Mixed Germ Cell Tumor, Ovarian Monodermal and Highly Specialized Teratoma, Ovarian Polyembryoma, Ovarian Yolk Sac Tumor, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Testicular Choriocarcinoma, Testicular Choriocarcinoma and Embryonal Carcinoma, Testicular Choriocarcinoma and Seminoma, Testicular Choriocarcinoma and Teratoma, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma, Testicular Embryonal Carcinoma and Seminoma, Testicular Embryonal Carcinoma and Teratoma, Testicular Embryonal Carcinoma and Teratoma With Seminoma, Testicular Embryonal Carcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor, Testicular Yolk Sac Tumor and Teratoma, Testicular Yolk Sac Tumor and Teratoma With Seminoma
Interventions
ipilimumab, therapeutic allogeneic lymphocytes
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 21, 2026, 2:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant

NCT03330795
View directory record Official record
Conditions
Primary Immunodeficiency, PID
Interventions
CD3/CD19 neg allogeneic BMT
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 21, 2026, 2:43 PM EDT